Arthneeti

Parnax Lab Share Price & Earnings Call Analysis

₹103.72-3.07% today
Market cap
₹119 Cr
P/E
11.87
ROE
14.16%
PEG
0.87
Price to sales
0.47
Debt to equity
0.87
52W high / low
₹165 / ₹103
Sales growth (5Y)
22.51%
EBITDA margin
9.57%
Net profit margin
5.09%
Promoter holding
72.30%
Sales (last year)
₹252 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Parnax Lab rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Parnax Lab.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Parnax Lab

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Parnax Lab

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +46.8240.9148.7442.6150.9946.3750.1248.3640.2249.0453.3862.6062.94
Expenses +39.4436.1842.2437.3245.0240.5841.5041.1235.9542.4145.9454.5256.09
Operating Profit7.384.736.505.295.975.798.627.244.276.637.448.086.85
OPM %15.76%11.56%13.34%12.41%11.71%12.49%17.20%14.97%10.62%13.52%13.94%12.91%10.88%
Other Income +0.080.270.240.220.100.250.110.950.190.430.180.63-0.17
Interest1.301.181.161.431.351.411.501.381.231.281.221.401.47
Depreciation1.741.591.601.741.781.841.831.941.791.831.942.101.96
Profit before tax4.422.233.982.342.942.795.404.871.443.954.465.213.25
Tax %28.51%35.43%16.33%20.09%25.85%19.35%26.30%29.77%16.67%26.08%26.46%30.33%16.62%
Net Profit +3.161.443.331.872.182.243.993.421.212.933.283.622.71
EPS in Rs2.741.252.891.631.901.953.472.971.052.542.853.162.36

Financials of Parnax Lab

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +7010371951061099590163168189188228
Expenses +6291618295998980140145165161199
Operating Profit812101310106102323242729
OPM %12%12%14%14%10%9%7%11%14%14%12%14%13%
Other Income +1110121001111
Interest4445445555555
Depreciation2334444567778
Profit before tax353535-2-01212121617
Tax %27%22%28%22%65%28%48%350%33%30%20%26%
Net Profit +243413-3-089101213
EPS in Rs2.935.012.954.331.233.88-3.42-0.428.407.518.3710.0310.91
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Parnax Lab

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital888888881011111111
Reserves12171923242724243851607278
Borrowings +33414239374251596955817069
Other Liabilities +29171015181723153628383750
Total Liabilities838379868795107106153145190190208
Fixed Assets +363638474451586072778988113
CWIP1120003532212914
Investments1110000000000
Other Assets +46453838434346417866807282
Total Assets838379868795107106153145190190208

Financials of Parnax Lab

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +-0-0316139969211632
Cash from Investing Activity +-6-4-6-10-5-11-13-7-16-10-32-16
Cash from Financing Activity +661-5-715012-1415-16
Net Cash Flow01-201-10-04-3-10
Free Cash Flow-6-4-358-3-4-0-811-1616
CFO/OP7%15%46%134%134%99%153%71%38%103%79%130%

Financials of Parnax Lab

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days13084100726564886885616360
Inventory Days1433864504552768073799487
Days Payable2035130484544744681537472
Cash Conversion Cycle71711347464729010277868375
Working Capital Days21167-26-80-31-66-35-19-23-24
ROCE %15%16%11%14%11%12%3%6%17%15%13%14%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals